Tonix Pharma Publishes Positive Phase 1 Data for TNX-1500, Advancing Organ Transplant & Autoimmune Candidate

summarizeSummary

Tonix Pharmaceuticals announced the publication of positive Phase 1 clinical data for TNX-1500, its drug candidate for organ transplant rejection and autoimmune diseases, showing a favorable safety profile and effective immune response blockade.

check_boxKey Events

• Positive Phase 1 Results Published

  Detailed data for TNX-1500, an Fc-modified anti-CD154 monoclonal antibody, was published in the peer-reviewed Journal of Clinical Immunology.

• Favorable Safety Profile

  TNX-1500 was generally well-tolerated across all doses (3 to 30 mg/kg) with no serious adverse events or thromboembolic complications, addressing a key safety concern for this class of drugs.

• Effective Immune Response Blockade

  The drug successfully blocked primary and secondary T cell-dependent antibody responses, indicating its potential in preventing organ transplant rejection and treating autoimmune diseases.

• Advancing to Phase 2

  An investigator-initiated Phase 2 study for kidney transplant rejection is expected to begin in the second half of 2026, pending FDA clearance of the IND application.

auto_awesomeAnalysis

This 8-K announces the publication of detailed positive Phase 1 clinical trial results for TNX-1500, an antibody designed for organ transplant rejection and autoimmune diseases. The data shows TNX-1500 was well-tolerated with no thromboembolic events, a critical safety improvement over prior generations of similar drugs, and effectively blocked immune responses. This positive development is significant for Tonix, which has recently faced "going concern" warnings and is preparing for a reverse stock split, as it provides a much-needed positive clinical milestone and potential future value driver. A Phase 2 study is expected to start in H2 2026.